Campbell & CO Investment Adviser LLC Buys Shares of 13,670 Core Laboratories (NYSE:CLB)

Campbell & CO Investment Adviser LLC bought a new position in shares of Core Laboratories (NYSE:CLB) in the 3rd quarter, according to its most recent 13F filing with the SEC. The fund bought 13,670 shares of the oil and gas company’s stock, valued at approximately $209,000.

A number of other hedge funds and other institutional investors have also recently modified their holdings of CLB. Squarepoint Ops LLC increased its stake in Core Laboratories by 158.3% during the 1st quarter. Squarepoint Ops LLC now owns 16,470 shares of the oil and gas company’s stock worth $170,000 after purchasing an additional 10,094 shares in the last quarter. Voloridge Investment Management LLC grew its holdings in shares of Core Laboratories by 69.5% during the first quarter. Voloridge Investment Management LLC now owns 110,808 shares of the oil and gas company’s stock worth $1,146,000 after buying an additional 45,439 shares in the last quarter. Morgan Stanley raised its position in Core Laboratories by 137.3% in the 1st quarter. Morgan Stanley now owns 876,426 shares of the oil and gas company’s stock valued at $9,062,000 after buying an additional 507,141 shares during the last quarter. California Public Employees Retirement System lifted its stake in Core Laboratories by 7.9% in the 2nd quarter. California Public Employees Retirement System now owns 98,172 shares of the oil and gas company’s stock valued at $1,995,000 after acquiring an additional 7,214 shares in the last quarter. Finally, First Trust Advisors LP boosted its position in Core Laboratories by 686.6% during the 2nd quarter. First Trust Advisors LP now owns 96,200 shares of the oil and gas company’s stock worth $1,955,000 after acquiring an additional 83,970 shares during the last quarter. Hedge funds and other institutional investors own 94.46% of the company’s stock.

Shares of Core Laboratories stock opened at $14.85 on Friday. The company has a debt-to-equity ratio of 4.33, a current ratio of 1.93 and a quick ratio of 1.51. The business has a fifty day simple moving average of $17.68 and a two-hundred day simple moving average of $18.99. Core Laboratories has a 1 year low of $6.68 and a 1 year high of $49.22. The company has a market capitalization of $660.59 million, a price-to-earnings ratio of -8.20, a P/E/G ratio of 6.95 and a beta of 3.15.

Core Laboratories (NYSE:CLB) last posted its earnings results on Wednesday, July 22nd. The oil and gas company reported $0.14 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.10 by $0.04. Core Laboratories had a negative net margin of 13.39% and a positive return on equity of 46.27%. The company had revenue of $115.74 million during the quarter, compared to analysts’ expectations of $115.43 million. As a group, equities analysts anticipate that Core Laboratories will post 0.8 earnings per share for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, November 17th. Stockholders of record on Monday, October 26th will be issued a dividend of $0.01 per share. This represents a $0.04 dividend on an annualized basis and a dividend yield of 0.27%. The ex-dividend date is Friday, October 23rd. Core Laboratories’s dividend payout ratio is presently 2.23%.

Several research analysts recently commented on CLB shares. Morgan Stanley increased their target price on shares of Core Laboratories from $18.00 to $24.00 and gave the stock an “equal weight” rating in a report on Wednesday, July 8th. Scotiabank downgraded shares of Core Laboratories from a “sector outperform” rating to a “sector perform” rating and set a $19.00 price objective for the company. in a research note on Thursday, July 16th. ValuEngine cut Core Laboratories from a “hold” rating to a “sell” rating in a report on Saturday, September 26th. ABN Amro upgraded Core Laboratories from a “sell” rating to a “hold” rating in a report on Tuesday, September 29th. Finally, Bank of America raised Core Laboratories from an “underperform” rating to a “neutral” rating in a research report on Tuesday, October 13th. One equities research analyst has rated the stock with a sell rating, thirteen have assigned a hold rating and two have assigned a buy rating to the company’s stock. The company has an average rating of “Hold” and an average target price of $26.96.

Core Laboratories Profile

Core Laboratories N.V. provides reservoir description and production enhancement services and products to the oil and gas industry in the United States, Canada, and internationally. The company operates in two segments, Reservoir Description and Production Enhancement segments. The Reservoir Description segment includes the characterization of petroleum reservoir rock, fluid, and gas samples to enhance production and improve recovery of oil and gas from its clients' reservoirs.

Featured Article: SEC Filing

Want to see what other hedge funds are holding CLB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Core Laboratories (NYSE:CLB).

Institutional Ownership by Quarter for Core Laboratories (NYSE:CLB)

Receive News & Ratings for Core Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Core Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.